Signals for increase of μ-opioid receptor expression in muscle by hyperglycemia

Neuroscience Letters

Volumn 582, Issue , 2014, Pages 109-114

  Yeh, Meng Ching ^a   Chen, Li Jen ^b,c   Niu, Ho Shan ^c   Yang, Ting Ting ^d   Lin, Kao Chang ^e,f   Cheng, Juei Tang ^e,g  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c TZU CHI COLLEGE OF TECHNOLOGY   (Taiwan)

^d I SHOU UNIVERSITY   (Taiwan)

^e CHI MEI MEDICAL CENTER   (Taiwan)

^f SOUTHERN TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^g CHANG JUNG CHRISTIAN UNIVERSITY   (Taiwan)

Author keywords

L6 cells; SiRNA; STAT3; Type 1 diabetes; Opioid receptor

Indexed keywords

GLUCOSE; LOPERAMIDE; MU OPIATE RECEPTOR; SMALL INTERFERING RNA; STAT3 PROTEIN; STREPTOZOCIN; STAT3 PROTEIN, RAT; STATTIC; SULFOXIDE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HYPERGLYCEMIA; HYPOGLYCEMIA; IN VIVO STUDY; INCUBATION TIME; MALE; MYOBLAST; NONHUMAN; PROTEIN EXPRESSION; RAT; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CHEMICALLY INDUCED; EXPERIMENTAL DIABETES MELLITUS; GENETICS; METABOLISM; WISTAR RAT;

ANIMALS; CELLS, CULTURED; CYCLIC S-OXIDES; DIABETES MELLITUS, EXPERIMENTAL; GLUCOSE; HYPERGLYCEMIA; LOPERAMIDE; MALE; MUSCLE, SKELETAL; MYOBLASTS, SKELETAL; RATS, WISTAR; RECEPTORS, OPIOID, MU; RNA, SMALL INTERFERING; STAT3 TRANSCRIPTION FACTOR; STREPTOZOCIN;

EID: 84907907851     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2014.09.008     Document Type: Article

References (35)

1. Boengler K., Ungefug E., Heusch G., Schulz R. The STAT3 inhibitor stattic impairs cardiomyocyte mitochondrial function through increased reactive oxygen species formation. Curr. Pharm. Des. 2013, 19:6890-6895.
2. Brosius F.C., Alpers C.E. New targets for treatment of diabetic nephropathy: what we have learned from animal models. Curr. Opin. Nephrol. Hypertens. 2013, 22:17-25.
3. Chen Y., Wang J.J., Li J., Hosoya K.I., Ratan R., Townes T., Zhang S.X. Activating transcription factor 4 mediates hyperglycaemia-induced endothelial inflammation and retinal vascular leakage through activation of STAT3 in a mouse model of type 1 diabetes. Diabetologia 2012, 55:2533-2545.
4. Cheng J.T., Huang C.C., Liu I.M., Tzeng T.F., Chang C.J. Novel mechanism for plasma glucose-lowering action of metformin in streptozotocin-induced diabetic rats. Diabetes 2006, 55:819-825.
5. Cheng J.T., Liu I.M., Chi T.C., Tzeng T.F. Increase of opioid mu-receptor gene expression in streptozotocin-induced diabetic rats. Horm. Metab. Res. 2001, 33:467-471.
6. Cheng K.C., Asakawa A., Li Y.X., Liu I.M., Amitani H., Cheng J.T., Inui A. Opioid mu-receptors as new target for insulin resistance. Pharmacol. Ther. 2013, 139:334-340.
7. Ding Y.Q., Kaneko T., Nomura S., Mizuno N. Immunohistochemical localization of mu-opioid receptors in the central nervous system of the rat. J. Comp. Neurol. 1996, 367:375-402.
8. Fiaschi T., Magherini F., Gamberi T., Lucchese G., Faggian G., Modesti A., Modesti P.A. Hyperglycemia and angiotensin II cooperate to enhance collagen I deposition by cardiac fibroblasts through a ROS-STAT3-dependent mechanism. Biochim. Biophys. Acta 2014, 1843:2603-2610.
9. Goldsmith J.R., Uronis J.M., Jobin C. Mu opioid signaling protects against acute murine intestinal injury in a manner involving Stat3 signaling. Am. J. Pathol. 2011, 179:673-683.
10. Holzer P. Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans. Neurosci. Lett. 2004, 361:192-195.
11. Huang C.J., Liu I.M., Cheng J.T. Increase of peroxisome proliferator-activated receptor delta gene expression in the lungs of streptozotocin-induced diabetic rats. Pulm. Pharmacol. Ther. 2007, 20:69-74.
12. Jung J.E., Lee H.G., Cho I.H., Chung D.H., Yoon S.H., Yang Y.M., Lee J.W., Choi S., Park J.W., Ye S.K., Chung M.H. STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells. FASEB J. 2005, 19:1296-1298.
13. Ku P.M., Chen L.J., Liang J.R., Cheng K.C., Li Y.X., Cheng J.T. Molecular role of GATA binding protein 4 (GATA-4) in hyperglycemia-induced reduction of cardiac contractility. Cardiovasc. Diabetol. 2011, 10:57.
14. Li X., Cai Y., Wang Y.S., Shi Y.Y., Hou W., Xu C.S., Wang H.Y., Ye Z., Yao L.B., Zhang J. Hyperglycaemia exacerbates choroidal neovascularisation in mice via the oxidative stress-induced activation of STAT3 signalling in RPE cells. PLoS ONE 2012, 7:e47600.
15. Liu I.M., Cheng J.T. Mediation of endogenous beta-endorphin in the plasma glucose-lowering action of herbal products observed in type 1-like diabetic rats. Evid. Based Complement. Alternat. Med. 2011, 2011:987876.
16. Liu I.M., Chi T.C., Chen Y.C., Lu F.H., Cheng J.T. Activation of opioid mu-receptor by loperamide to lower plasma glucose in streptozotocin-induced diabetic rats. Neurosci. Lett. 1999, 265:183-186.
17. Mair M., Blaas L., Osterreicher C.H., Casanova E., Eferl R. JAK-STAT signaling in hepatic fibrosis. Front. Biosci. 2011, 16:2794-2811.
18. Martini L., Whistler J.L. The role of mu opioid receptor desensitization and endocytosis in morphine tolerance and dependence. Curr. Opin. Neurobiol. 2007, 17:556-564.
19. Miller A.M., Wang H., Bertola A., Park O., Horiguchi N., Ki S.H., Yin S., Lafdil F., Gao B. Inflammation-associated interleukin-6/signal transducer and activator of transcription 3 activation ameliorates alcoholic and nonalcoholic fatty liver diseases in interleukin-10-deficient mice. Hepatology 2011, 54:846-856.
20. Montesinos R.N., Moulari B., Gromand J., Beduneau A., Lamprecht A., Pellequer Y. Coadministration of P-glycoprotein modulators on loperamide pharmacokinetics and brain distribution. Drug Metab. Dispos. 2014, 42:700-706.
21. Nitin N., Carlson A.L., Muldoon T., El-Naggar A.K., Gillenwater A., Richards-Kortum R. Molecular imaging of glucose uptake in oral neoplasia following topical application of fluorescently labeled deoxy-glucose. Int. J. Cancer 2009, 124:2634-2642.
22. Niu C.S., Chen L.J., Niu H.S. Antihyperglycemic action of Rhodiola-aqueous extract in type 1-like diabetic rats. BMC Complement. Alternat. Med. 2014, 14:20.
23. Osorio-Fuentealba C., Contreras-Ferrat A.E., Altamirano F., Espinosa A., Li Q., Niu W., Lavandero S., Klip A., Jaimovich E. Electrical stimuli release ATP to increase GLUT4 translocation and glucose uptake via PI3Kgamma-Akt-AS160 in skeletal muscle cells. Diabetes 2013, 62:1519-1526.
24. Pan Y., Zhou F., Zhang R., Claret F.X. Stat3 inhibitor stattic exhibits potent antitumor activity and induces chemo- and radio-sensitivity in nasopharyngeal carcinoma. PLOS ONE 2013, 8:e54565.
25. Pugliese A. The multiple origins of type 1 diabetes. Diabet. Med.: J. Br. Diabet. Assoc. 2013, 30:135-146.
26. Schena F.P., Gesualdo L. Pathogenetic mechanisms of diabetic nephropathy. J. Am. Soc. Nephrol. 2005, 16(Suppl. 1):S30-S33.
27. Sun X., Chen R.C., Yang Z.H., Sun G.B., Wang M., Ma X.J., Yang L.J., Sun X.B. Taxifolin prevents diabetic cardiomyopathy in vivo and in vitro by inhibition of oxidative stress and cell apoptosis. Food Chem. Toxicol.: Int. J. Br. Ind. Biol. Res. Assoc. 2014, 63:221-232.
28. Szelag M., Sikorski K., Czerwoniec A., Szatkowska K., Wesoly J., Bluyssen H.A. In silico simulations of STAT1 and STAT3 inhibitors predict SH2 domain cross-binding specificity. Eur. J. Pharmacol. 2013, 720:38-48.
29. Tremblay J., Hamet P. Genetics of pain, opioids, and opioid responsiveness. Metabolism 2010, 59(Suppl. 1):S5-S8.
30. Vinik A.I., Cincotta A.H., Scranton R.E., Bohannon N., Ezrokhi M., Gaziano J.M. Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents. Endocr. Pract. 2012, 1-34.
31. Watson A.J., Gao L., Sun L., Tsun J., Jabbour A., Ru Qiu M., Jansz P.C., Hicks M., Macdonald P.S. Enhanced preservation of the rat heart after prolonged hypothermic ischemia with erythropoietin-supplemented Celsior solution. J. Heart Lung Transplant. 2013, 32:633-640.
32. Wei L.N., Loh H.H. Transcriptional and epigenetic regulation of opioid receptor genes: present and future. Annu. Rev. Pharmacol. Toxicol. 2011, 51:75-97.
33. Yu B.C., Chang C.K., Ou H.Y., Cheng K.C., Cheng J.T. Decrease of peroxisome proliferator-activated receptor delta expression in cardiomyopathy of streptozotocin-induced diabetic rats. Cardiovasc. Res. 2008, 80:78-87.
34. Zadina J.E. Isolation and distribution of endomorphins in the central nervous system. Jpn. J. Pharmacol. 2002, 89:203-208.
35. Zhou Y., Sridhar R., Shan L., Sha W., Gu X., Sukumar S. Loperamide, an FDA-approved antidiarrhea drug, effectively reverses the resistance of multidrug resistant MCF-7/MDR1 human breast cancer cells to doxorubicin-induced cytotoxicity. Cancer Invest. 2012, 30:119-125.